(PDF) OA06 Tepotinib in Non-Small Cell Lung Cancer With MET

OA06 Tepotinib in Non-Small Cell Lung Cancer With MET Exon 14-Skipping Mutations or MET Amplification: A Phase 2 Trial in Progress

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.10.016

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

December 1, 2018

Authors

Publisher

Elsevier BV

Related search

OA12.01 Phase II Data for the MET Inhibitor Tepotinib in Patients With Advanced NSCLC and MET Exon 14-Skipping Mutations

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.13-41 in Vitro Evaluation for Optimal MET-TKI Selection in Lung Cancers With MET Mutations Including Exon 14 Skipping

Journal of Thoracic Oncology

Respiratory Medicine

English

Characterization of 298 Patients With Lung Cancer Harboring MET Exon 14 Skipping Alterations

Journal of Thoracic Oncology

Respiratory Medicine

English

OA14 Phase 2 Study: Tepotinib + Gefitinib in MET+/Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

OA12.02 Updated Antitumor Activity of Crizotinib in Patients With MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Brief Report: DNA-based Versus RNA-based Detection of MET Exon 14 Skipping Events in Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.09-18 Identification of MET Exon 14 Skipping Mutations by FusionPlexTM Solid Tumor Panel

Journal of Thoracic Oncology

Respiratory Medicine

English

Crizotinib in MET Deregulated or ROS1 Rearranged Pretreated Non-Small-Cell Lung Cancer (METROS): A Phase II, Prospective, Multicentre, Two-Arms Trial

Clinical Cancer Research

Cancer Research

English

P020 Characterization of Met Exon 14 Skipping and Association With Clinical Outcomes of Crizotinib in Chinese Lung Cancers

Journal of Thoracic Oncology

Respiratory Medicine

English